Default company panoramic image
Logo

Eydo Pharma

Eydo is devoted to the R&D of unique antibacterials for controlling bacterial resistance, a worldwide issue of Public Health.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Vincennes, IDF, France
  • Currency USD
  • Founded June 2004
  • Employees 5
  • Website eydolabs.fr

Company Summary

Eydo Pharma is a privately-held French-based DDS company dedicated to R&D of patented innovative green nanomedicine technologies for the control of bacterial diseases. Its major project is a breakthrough natural drug candidate with an unparalleled antibacterial broad spectrum including panresistant strains of bacteria. The company aims to provide pharma industry with unique products to control the emerging worlwide issue of bacterial resistance.

Team

  • Default avatar
    Elisabeth Rossines
    President

    Founder of the company, President and VP Innovation & R&D, Elisabeth is a recognized plants & EOs specialist and was officer or founder of several companies.

  • Default avatar
    Daniel Henry
    CEO

    Daniel is highly experienced in healthcare sectors (pharmaceuticals, OTC, nutraceuticals, IVD…) and former CEO at Merck KGaA France ; he is also current non-executive Chairman at Phynova LTD.

  • Default avatar
    Olivier Chiarisoli
    Chairman of the supervisory board

    Olivier (DVM) has a dual professional experience in the pharmaceutical industry and in venture capital ; he is also specialist in natural medicines. Former President & CEO at Sud-Partners (venture capital), he is current President at Ago Pharma (holding company).

Advisors

  • Default avatar
    Cabinet Ratheaux (Lyon, France)
    Lawyer
    Unconfirmed
    Default avatar
    Cabinet Amperex (Paris, France)
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    FCPR Emergence Innovation 1 (Sofimac Partners, Clermont-Ferrand)
    Unconfirmed
    Default avatar
    Ago Pharma (Olivier Chiarisoli, Paris)
    Unconfirmed